ArticleFrontiers in cardiovascular medicine2022
Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy.
Shalin Rawal et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.